Saltar al contenido
Merck

Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans.

Cell reports (2019-05-03)
Min Ni, Ashley Solmonson, Chunxiao Pan, Chendong Yang, Dan Li, Ashley Notzon, Ling Cai, Gerardo Guevara, Lauren G Zacharias, Brandon Faubert, Hieu S Vu, Lei Jiang, Bookyung Ko, Noriko Merida Morales, Jimin Pei, Gonçalo Vale, Dinesh Rakheja, Nick V Grishin, Jeffrey G McDonald, Garrett K Gotway, Markey C McNutt, Juan M Pascual, Ralph J DeBerardinis
RESUMEN

Inborn errors of metabolism (IEMs) link metabolic defects to human phenotypes. Modern genomics has accelerated IEM discovery, but assessing the impact of genomic variants is still challenging. Here, we integrate genomics and metabolomics to identify a cause of lactic acidosis and epilepsy. The proband is a compound heterozygote for variants in LIPT1, which encodes the lipoyltransferase required for 2-ketoacid dehydrogenase (2KDH) function. Metabolomics reveals abnormalities in lipids, amino acids, and 2-hydroxyglutarate consistent with loss of multiple 2KDHs. Homozygous knockin of a LIPT1 mutation reduces 2KDH lipoylation in utero and results in embryonic demise. In patient fibroblasts, defective 2KDH lipoylation and function are corrected by wild-type, but not mutant, LIPT1 alleles. Isotope tracing reveals that LIPT1 supports lipogenesis and balances oxidative and reductive glutamine metabolism. Altogether, the data extend the role of LIPT1 in metabolic regulation and demonstrate how integrating genomics and metabolomics can uncover broader aspects of IEM pathophysiology.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido cítrico, ACS reagent, ≥99.5%
Sigma-Aldrich
Anti-β-actina monoclonal, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
Ácido succínico, BioXtra, BioRenewable, ≥99.0%
Sigma-Aldrich
Anti-LIPT1 antibody produced in rabbit, affinity isolated antibody